Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

DSpace Repository

Show simple item record

dc.contributor.author Garbe, Claus
dc.date.accessioned 2019-07-10T06:43:28Z
dc.date.available 2019-07-10T06:43:28Z
dc.date.issued 2018
dc.identifier.issn 1569-8041
dc.identifier.uri http://hdl.handle.net/10900/90201
dc.language.iso en de_DE
dc.publisher Oxford Univ Press de_DE
dc.relation.uri http://dx.doi.org/10.1093/annonc/mdy408 de_DE
dc.subject.ddc 610 de_DE
dc.title Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer de_DE
dc.type Article de_DE
utue.quellen.id 20190321153956_00484
utue.publikation.seiten 2208-2213 de_DE
utue.personen.roh Long, G. V.
utue.personen.roh Tykodi, S. S.
utue.personen.roh Schneider, J. G.
utue.personen.roh Garbe, C.
utue.personen.roh Gravis, G.
utue.personen.roh Rashford, M.
utue.personen.roh Agrawal, S.
utue.personen.roh Grigoryeva, E.
utue.personen.roh Bello, A.
utue.personen.roh Roy, A.
utue.personen.roh Rollin, L.
utue.personen.roh Zhao, X.
dcterms.isPartOf.ZSTitelID Annals of Oncology de_DE
dcterms.isPartOf.ZS-Issue 11 de_DE
dcterms.isPartOf.ZS-Volume 29 de_DE
utue.fakultaet 04 Medizinische Fakultät de_DE


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record